Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels

1. A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of one or more active agents to a subject, comprising as a permeation enhancing mixture:

a fatty component in an amount of 0.1% to 20% by weight and comprising one of a saturated fatty alcohol of formula CH 3 —(CH 2 ) n —CH 2 OH, a saturated fatty acid of formula CH 3 —(CH 2 ) n —CH 2 COOH, an unsaturated fatty alcohol of formula CH 3 (C n H 2(n-1) )—OH, or a fatty acid of formula CH 3 (C n H 2(n-1) )—COOH, wherein n is an integer of between 8 and 22; and

a vehicle comprising 5% to 75% by weight of a C 1 –C 4 alkanol, 0.5% to 50% of a polyalcohol, water, and up to 40% by weight of a monoalkylether of diethyleneglycol, with all weights calculated based on the total weight of the composition and provided that the total weights of the components does not exceed 100%,

wherein the one or more active agents are selected from the group consisting of an androgen hormone, an antihypothyroid hormone, an antihypertensive agent, and a calcium regulator.

2. The pharmaceutical composition of claim 1 , wherein the fatty component is present in an amount of 0.1% to 10%, the alkanol is present in an amount of 15% to 65%, the polyalcohol is present in an amount of 3% to 20%, and the monoalkylether of diethyleneglycol is present in an amount of 0.2% to 25%.

3. The pharmaceutical composition of claim 2 , wherein the fatty component is present in an amount of 0.2% to 3%, the alkanol is present in an amount of 20% to 55%, the polyalcohol is present in an amount of 4% to 10%, and the monoalkylether of diethyleneglycol is present in an amount of 2% to 8%.

4. A pharmaceutical composition in the form of a gel for transdermal or transmucosal administration of one or more active agents to a subject, comprising as a permeation enhancing mixture

a fatty component in an amount of 0.2% to 3% by weight and comprising one of a saturated fatty alcohol of formula CH 3 —(CH 2 ) n —CH 2 OH, a saturated fatty acid of formula CH 3 —(CH 2 ) n —CH 2 COOH, an unsaturated fatty alcohol of formula CH 3 (C n H 2(n-1) )—OH, or a fatty acid of formula CH 3 (C n H 2(n-1) )—COOH, wherein n is an integer of between 8 and 22, and

a vehicle comprising 20% to 55% by weight of a C 1 –C 4 alkanol, 4% to 10% of a polyalcohol, water, and 2% to 8% by weight of a monoalkylether of diethyleneglycol;

a gelling agent in an amount of 0.2 to 3% by weight; and a pH regulator in an amount of 0.05% to 2% by weight, with the weights calculated based on the total weight of the composition and the total weights of the components not exceeding 100%

wherein the one or more active agent are selected from the group consisting of an androgen hormone, a sedative or anxyolitic, an antihypothyroid hormone, an antihypertensive agent, and a calcium regulator.

5. The pharmaceutical composition of claim 4 , wherein the gelling agent is a polyacrylic acid or a cellulose derivative.

6. The pharmaceutical composition of claim 5 , wherein the gelling agent is carbopol, hydroxypropylmethylcellulose, carboxymethylcellulose, ethylhydroxyethyl cellulose, hydroxypropylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, a polyoxyethylene/polyoxypropylene copolymer, polyvinylalcohol, a natural gum, an alginate, or a pectin.

7. The pharmaceutical composition of claim 4 , wherein the fatty component is a saturated or unsaturated fatty alcohol where n is an integer of between 8 and 12, the polyalcohol is a glycol, the alkanol is ethanol, the monoalkylether of diethyleneglycol is diethylene glycol monoethylether and the pH regulator is an tertiary amine or sodium hydroxide.

8. The pharmaceutical composition of claim 7 , wherein the fatty component is lauryl alcohol or dodecanol, the polyalcohol is propylene glycol and the pH regulator is triethanolamine or tromethamine.

9. A pharmaceutical composition in the form of a solution, cream, lotion, spray, ointment, gel, aerosol, tablet, suppository or patch device for transdermal or transmucosal administration of one or more active agents to a subject, comprising as a permeation enhancing mixture:

a fatty component in an amount of 0.1% to 20% by weight and comprising one of a saturated fatty alcohol of formula CH 3 —(CH 2 ) n —CH 2 OH, a saturated fatty acid of formula CH 3 —(CH 2 ) n —CH 2 COOH, an unsaturated fatty alcohol of formula CH 3 (C n H 2(n-1) )—OH, or a fatty acid of formula CH 3 (C n H 2(n-1) )—COOH, wherein n is an integer of between 8 and 22;

a vehicle comprising 5% to 75% by weight of a C 1 –C 4 alkanol, 0.5% to 50% of a polyalcohol, water, and up to 40% by weight of a monoalkylether of diethyleneglycol, with all weights calculated based on the total weight of the composition and provided that the total weights of the components does not exceed 100%, and

one or more of a flavor agent, saborizant, sweetener or solubilizant in an amount sufficient to impart desired properties to the composition;

wherein the one or more active agents are selected from the group consisting of an androgen hormone, a sedative or anxyolitic, an antihypothyroid hormone, an antihypertensive agent, and a calcium regulator.

10. The pharmaceutical composition of claim 1 , wherein the active agent is an androgen hormone.

11. The pharmaceutical composition of claim 10 , wherein the androgen hormone is Testosterone or a Testosterone derivatives selected from the group consisting of 17-Methyltestosterone, Testosterone 17 beta-Cypionate, Testosterone Enanthate, Testosterone Nicotinate, Testosterone Phenylacetate, or Testosterone Propionate.

12. The pharmaceutical composition of claim 4 , wherein the active agent is a sedative or anxyolitic.

13. The pharmaceutical composition of claim 12 , wherein the sedative or anxyolitic is a benzodiazepine or an amide.

14. The pharmaceutical composition of claim 13 , wherein the sedative or anxyolitic is butoctamide, diethylbromoacetamide, or isovalcryl-diethylamide.

15. The pharmaceutical composition of claim 1 , wherein the active agent is an antihypothyroid hormone.

16. The pharmaceutical composition of claim 1 , wherein the active agent is an antihypertensive agent.

17. The pharmaceutical composition of claim 1 , wherein the active agent is a calcium regulator.

18. The pharmaceutical composition of claim 17 , wherein the calcium regulator is calcitonin, calcifediol, or parathyroid hormone.

19. A pharmaceutical composition in the form of a gel for transdermal or transmucosal administration of an androgen hormone to a subject, comprising as a permeation enhancing mixture:

a fatty component in an amount of 0.1% to 20% by weight and comprising one of a saturated or unsaturated fatty alcohol of formula CH 3 —(CH 2 ) n —CH 2 OH, wherein n is an integer of between 8 and 12;

a vehicle comprising 5% to 75% by weight of ethanol, 0.5% to 50% of propylene glycol, water, and 0.2 to 40% by weight of diethylene glycol monoethylether;

a gelling agent of carbopol or a cellulose derivative in an amount of 0.2 to 3% by weight;

a pH regulator of a tertiary amine or sodium hydroxide in an amount of 0.05% to 2% by weight, with all weights calculated based on the total weight of the composition and provided that the total weights of the components does not exceed 100%; and

optionally, one or more of a flavor agent, saborizant, sweetener or solubilizant in an amount sufficient to impart desired properties to the composition.